Kit for LAMP (loop-mediated isothermal amplification) detection of HPgV-1 virus

Through the LAMP detection kit and specific primer set, the problem of slow detection speed and low accuracy of HPgV-1 virus is solved, and fast and accurate viral nucleic acid detection is achieved, which significantly improves the detection speed and sensitivity, and ensures the purity of the detection results. and accuracy.

CN119061207AInactive Publication Date: 2024-12-03TAIZHOU FOURTH PEOPLES HOSPITAL
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202411518488.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-10-29
Publication Date
2024-12-03
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The existing HPgV-1 virus detection methods such as RT-PCR and ELISA have problems such as long detection cycles, slow speeds, complex equipment, high operating skills, inconsistent results and inability to directly detect viral RNA, which limits their clinical diagnosis and large-scale Application in screening.

Method used

A LAMP detection kit for HPgV-1 virus was developed, including reaction solution, sample treatment solution, HPgV-1 virus negative control and positive control, using UTR1, UTR2, UTR3, UTR4 and NS5 primer sets, combined with constant temperature expansion Increase the system to achieve fast and accurate viral nucleic acid detection.

Benefits of technology

It is achieved within 40 minutes from sample extraction to result determination, and the sensitivity reaches 1 copy per microliter, which significantly improves the detection speed and accuracy, avoids cross-contamination and misjudgment, and ensures the purity and accuracy of the detection results.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119061207A_ABST
    Figure CN119061207A_ABST
Patent Text Reader

Abstract

The invention relates to a kit for LAMP (Loop-Mediated Isothermal Amplification) detection of HPgV-1 virus, which belongs to the technical field of virus detection and comprises the following components: reaction liquid, sample treatment liquid, HPgV-1 virus negative control and HPgV-1 virus positive control, wherein the reaction liquid comprises an isothermal amplification system and a primer group. Compared with conventional HPgV-1 virus detection methods such as fluorescent quantitative PCR (polymerase chain reaction), the LAMP method established by the invention is quicker and more efficient, the process from sample extraction to result judgment can be completed within 40 minutes, and the reaction result judgment method is simple, high in detection sensitivity and strong in specificity.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of virus detection, and in particular, relates to a kit for HPgV-1 virus LAMP detection. Background Art

[0002] Human pegivirus-1 (HPgV-1) is a widespread single-stranded positive RNA virus of the Flaviviridae family, which is mainly transmitted through blood transfusion, injection drug use, percutaneous injuries and sexual contact. About one-sixth of the world's population is HPgV-1 seropositive, and its prevalence varies significantly in different countries and regions. The prevalence of HPgV-1 infection in the general population is 0.8%-44.6%, while the infection rate in high-risk groups such as injection drug users and men who have sex with men is higher, reaching 1.8%-75.3%. Although HPgV-1 is generally considered a non-pathogenic and potentially beneficial virus, its ability to improve the survival of AIDS patients when co-infected with HIV-1 has raised concerns about its possible positive role in other human diseases.

[0003] Currently, the most commonly used method for detecting HPgV-1 infection is RT-PCR, which reverse-transcribes HPgV-1 RNA virus into cDNA, then uses cDNA as a template for PCR amplification, and the amplified product can be interpreted by gel electrophoresis. The RT-PCR method has high accuracy and can detect HPgV-1-RNA in serum or plasma and body fluids of patients with HPgV-1 viremia. However, the RT-PCR method has the problems of long detection cycle and slow speed, and requires complex experimental equipment and professional operation skills, which limits its application in clinical diagnosis and large-scale screening.

[0004] Another detection method is HPgV antibody detection based on ELISA technology, which uses solid-phase antigen adsorbents to capture HPgV antibodies in serum for interpretation. However, due to the lack of unified detection standards, different detection systems have caused large differences in results, making it impossible to make horizontal comparisons, and there is no consensus on the threshold of viral copy number, which has caused certain difficulties in interpreting reports. In addition, the ELISA method is only suitable for detecting HPgV antibodies and cannot directly detect viral RNA. Therefore, it may not be possible to accurately judge the infection status during the viremia period or early infection stage.

[0005] Based on the above description, it is necessary to develop a method that can quickly, effectively and accurately detect HPgV-1 virus. Summary of the invention

[0006] The purpose of the present invention is to provide a kit for HPgV-1 virus LAMP detection, which solves the problems raised in the background technology.

[0007] The purpose of the present invention can be achieved through the following technical solutions: A kit for HPgV-1 virus LAMP detection, comprising the following components: a reaction solution, a sample processing solution, a HPgV-1 virus negative control and a HPgV-1 virus positive control; The reaction solution includes a constant temperature amplification system and a primer set.

[0008] Furthermore, the primer set is at least one of a UTR1 primer set, a UTR2 primer set, a UTR3 primer set, a UTR4 primer set and a NS5 primer set.

[0009] Further, the UTR1 primer set includes F3 with a sequence as shown in SEQ ID NO: 1, B3 with a sequence as shown in SEQ ID NO: 2, FIP with a sequence as shown in SEQ ID NO: 3, BIP with a sequence as shown in SEQ ID NO: 4, and LB with a sequence as shown in SEQ ID NO: 5; The UTR2 primer set includes F3 with a sequence as shown in SEQ ID NO:6, B3 with a sequence as shown in SEQ ID NO:7, FIP with a sequence as shown in SEQ ID NO:8, BIP with a sequence as shown in SEQ ID NO:9, LF with a sequence as shown in SEQ ID NO:10, and LB with a sequence as shown in SEQ ID NO:11; The UTR3 primer set includes F3 with a sequence as shown in SEQ ID NO: 12, B3 with a sequence as shown in SEQ ID NO: 13, FIP with a sequence as shown in SEQ ID NO: 14, BIP with a sequence as shown in SEQ ID NO: 15, LF with a sequence as shown in SEQ ID NO: 16, and LB with a sequence as shown in SEQ ID NO: 17; The UTR4 primer set includes F3 with a sequence as shown in SEQ ID NO: 18, B3 with a sequence as shown in SEQ ID NO: 19, FIP with a sequence as shown in SEQ ID NO: 20, BIP with a sequence as shown in SEQ ID NO: 21, LF with a sequence as shown in SEQ ID NO: 22, and LB with a sequence as shown in SEQ ID NO: 23; The NS5 primer set includes F3 as shown in SEQ ID NO:24, B3 as shown in SEQ ID NO:25, FIP as shown in SEQ ID NO:26, BIP as shown in SEQ ID NO:27, LF as shown in SEQ ID NO:28, and LB as shown in SEQ ID NO:29.

[0010] The sequences of the primers in the UTR1 primer set, the UTR2 primer set, the UTR3 primer set, the UTR4 primer set and the NS5 primer set are shown in Table 1 below: Table 1

[0011] Furthermore, the LF or LB sequence in the UTR1 primer set, UTR2 primer set, UTR3 primer set, UTR4 primer set and NS5 primer set is modified with a fluorescent quenching group at its 5' end and a fluorescent reporter group at its 3' end.

[0012] Further, the fluorescent reporter group is selected from at least one of 6-carboxyfluorescein, hexachloro-6-methylfluorescein, VIC fluorescent dye, tetrachloro-6-carboxyfluorescein, carboxy-X-rhodamine, 6-carboxytetramethylrhodamine, 2,7-dimethyl-4,5-dichloro-6-carboxyfluorescein, sulfonylrhodamine, 6-carboxy-4',5-dichloro-2',7'-dimethoxyfluorescein succinimide ester, cyanine 3, cyanine 5 or cyanine 5.5.

[0013] Furthermore, the fluorescence quenching group is at least one of BHQ1, BHQ2, and BHQ3.

[0014] Furthermore, the isothermal amplification system includes 10× isothermal amplification buffer, DNA polymerase, MgCl2, dNTP, and nuclease-free water.

[0015] Furthermore, the DNA polymerase is Bst polymerase.

[0016] Furthermore, the method of using the method specifically comprises the following steps: S1. Collect samples to be tested; S2. Add the collected samples into a sample processing solution to extract viral nucleic acid; S3, adding the extracted viral nucleic acid to a kit for HPgV-1 virus LAMP detection, placing it in a thermostat, and performing LAMP amplification at a constant temperature; S4. After the amplification is completed, the amplified product is detected to determine whether the HPgV-1 virus exists in the sample.

[0017] Furthermore, in step S3, the LAMP amplification reaction temperature is 50-65° C., and the reaction time is 10-60 minutes.

[0018] Beneficial effects of the present invention: In the technical solution of the present invention, the established LAMP method is faster and more efficient than conventional HPgV-1 virus detection methods such as fluorescent quantitative PCR. The process from sample extraction to result determination can be completed within 40 minutes, and the reaction result determination method is simple. In the technical solution of the present invention, the primers used can reach a sensitivity of 1 copy per microliter, and a concentration of more than 10 copies / reaction can be stably detected, which is significantly higher than the existing technology level; the primers of the present invention can specifically detect HPgV-1 virus, and realize the accurate identification and efficient detection of target pathogens. Under strict experimental conditions, the method shows complete non-reactivity to a variety of common pathogens such as HBV (hepatitis B virus), HCV (hepatitis C virus), HAV (hepatitis A virus), HEV (hepatitis E virus), HIV (human immunodeficiency virus) and CMV (cytomegalovirus), ensuring the purity and accuracy of the test results, and effectively avoiding the risk of clinical misdiagnosis due to cross contamination or misjudgment. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] In order to more clearly illustrate the technical solutions of the embodiments of the present invention, the accompanying drawings required for describing the embodiments will be briefly introduced below. Obviously, the accompanying drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other accompanying drawings can be obtained based on these accompanying drawings without paying creative work.

[0020] Figure 1 This is a diagram showing the detection effect of the kit for HPgV-1 virus LAMP detection prepared in Example 1-5; Figure 2 The result diagram of the detection sensitivity test of the kit for HPgV-1 virus LAMP detection prepared in Example 3; Figure 3 This is a graph showing the specificity test results of the HPgV-1 virus LAMP detection kit sample prepared in Example 3. DETAILED DESCRIPTION

[0021] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0022] The vector used in the following examples is plasmid pcDNA3.1(+), which was synthesized by Sangon Biotech Co., Ltd.

[0023] Example 1 A kit for HPgV-1 virus LAMP detection, comprising the following components: a reaction solution, a sample processing solution, a HPgV-1 virus negative control and a HPgV-1 virus positive control; The reaction solution includes a constant temperature amplification system and a UTR1 primer set; Among them, the negative control of HPgV-1 virus was nuclease-free water; The specific components are shown in Table 2 below: Table 2

[0024] The usage is: S1. Collect samples to be tested and obtain serum samples; S2. Add the collected samples into the sample processing solution to extract viral nucleic acid. The specific operation is as follows: The serum samples were extracted using the GeneRotex 96 nucleic acid extractor. The specific extraction procedure is shown in Table 3 below: Table 3

[0025] S3, adding the extracted viral nucleic acid to a kit for HPgV-1 virus LAMP detection, placing it in a thermostat, and performing LAMP amplification at a constant temperature; The amplification reaction temperature was set to 63° C., and the amplification reaction time was set to 40 minutes.

[0026] S4. After amplification, detect the amplification product and collect the Cy5 fluorescence signal at the end of the cycle (instrument: Bio-Rad CFX96) to determine whether HPgV-1 virus exists in the sample.

[0027] Example 2 The difference between this embodiment and embodiment 1 is that the primer set used in this embodiment is UTR2.

[0028] Example 3 The difference between this embodiment and embodiment 1 is that the primer set used in this embodiment is UTR3.

[0029] Example 4 The difference between this embodiment and embodiment 1 is that the primer set used in this embodiment is UTR4.

[0030] Example 5 The difference between this embodiment and embodiment 1 is that the primer set used in this embodiment is NS5.

[0031] Now, the test kit for HPgV-1 virus LAMP detection prepared in Examples 1-5 is tested for detection effect. The method for determining the LAMP detection result is as follows: ① Positive control: A typical S-shaped amplification curve appears, and the end point fluorescence value is more than 3 times higher than the starting point fluorescence value, which is a valid result; ②Negative control: No amplification curve appears, or the end point fluorescence value is 3 times lower than the starting point fluorescence value, which is a valid result; ③ Samples tested: a. If the end point fluorescence value is 3 times higher than the starting point fluorescence value, it is judged as positive; b. If the endpoint fluorescence value is 3 times lower than the starting fluorescence value, it is judged as negative.

[0032] Specific test results such as Figure 1 shown.

[0033] according to Figure 1 The results show that the detection method of the HPgV-1 fluorescence isothermal amplification detection kit established in this embodiment can detect HPgV-1 in serum, and it takes less time than the conventional fluorescence quantitative PCR method. Among them, the conventional fluorescence quantitative PCR method is the fluorescence quantitative PCR method disclosed in the prior art (Matthew et al., Development of a high-throughput multiplexed real time RT-PCR assay for detection of human pegivirus 1 and 2, Journal of Virological Methods).

[0034] Now, the detection sensitivity of the kit for HPgV-1 virus LAMP detection prepared in Example 3 is tested.

[0035] Test results such as Figure 2 shown.

[0036] Now, the specificity test is performed on the samples of the HPgV-1 virus LAMP detection kit prepared in Example 3. One sample of HPgV-1 and seven samples of HBV, HCV, HAV, HEV, HIV, and CMV, which are verified as positive for the corresponding viruses by constant temperature amplification, are collected clinically for testing to verify the specificity of the kit.

[0037] Test results such as Figure 3 shown.

[0038] Depend on Figure 2 and Figure 3It can be seen from the results that the HPgV-1 virus LAMP detection kit and detection method provided in the present application can complete the detection of HPgV-1 virus strains within 40 minutes, with fast detection speed and simple operation, and can be widely used in the rapid differential diagnosis of HPgV-1 virus strains.

[0039] In the description of the specification, the description with reference to the terms "one embodiment", "example", "specific example", etc. means that the specific features, structures, materials or characteristics described in conjunction with the embodiment or example are included in at least one embodiment or example of the present invention. In this specification, the schematic representation of the above terms does not necessarily refer to the same embodiment or example. Moreover, the specific features, structures, materials or characteristics described can be combined in any one or more embodiments or examples in a suitable manner.

[0040] The above contents are merely examples and explanations of the concept of the present invention. The technicians in this technical field may make various modifications or additions to the specific embodiments described or replace them in a similar manner. As long as they do not deviate from the concept of the invention or exceed the scope defined by the claims, they should all fall within the protection scope of the present invention.

Claims

1. A kit for HPgV-1 virus LAMP detection, characterized in that: It includes the following components: reaction solution, sample treatment solution, HPgV-1 virus negative control and HPgV-1 virus positive control; The reaction solution includes a constant temperature amplification system and a primer set.

2. A kit for HPgV-1 virus LAMP detection according to claim 1, characterized in that: The primer set is at least one of a UTR1 primer set, a UTR2 primer set, a UTR3 primer set, a UTR4 primer set and a NS5 primer set.

3. A kit for HPgV-1 virus LAMP detection according to claim 2, characterized in that: The UTR1 primer set includes F3 with a sequence as shown in SEQ ID NO: 1, B3 with a sequence as shown in SEQ ID NO: 2, FIP with a sequence as shown in SEQ ID NO: 3, BIP with a sequence as shown in SEQ ID NO: 4, and LB with a sequence as shown in SEQ ID NO: 5; The UTR2 primer set includes F3 with a sequence as shown in SEQ ID NO:6, B3 with a sequence as shown in SEQ ID NO:7, FIP with a sequence as shown in SEQ ID NO:8, BIP with a sequence as shown in SEQ ID NO:9, LF with a sequence as shown in SEQ ID NO:10, and LB with a sequence as shown in SEQ ID NO:11; The UTR3 primer set includes F3 with a sequence as shown in SEQ ID NO: 12, B3 with a sequence as shown in SEQ ID NO: 13, FIP with a sequence as shown in SEQ ID NO: 14, BIP with a sequence as shown in SEQ ID NO: 15, LF with a sequence as shown in SEQ ID NO: 16, and LB with a sequence as shown in SEQ ID NO: 17; The UTR4 primer set includes F3 with a sequence as shown in SEQ ID NO: 18, B3 with a sequence as shown in SEQ ID NO: 19, FIP with a sequence as shown in SEQ ID NO: 20, BIP with a sequence as shown in SEQ ID NO: 21, LF with a sequence as shown in SEQ ID NO: 22, and LB with a sequence as shown in SEQ ID NO: 23; The NS5 primer set includes F3 as shown in SEQ ID NO:24, B3 as shown in SEQ ID NO:25, FIP as shown in SEQ ID NO:26, BIP as shown in SEQ ID NO:27, LF as shown in SEQ ID NO:28, and LB as shown in SEQ ID NO:

29.

4. A kit for HPgV-1 virus LAMP detection according to claim 3, characterized in that: The LF or LB sequence in the UTR1 primer set, the UTR2 primer set, the UTR3 primer set, the UTR4 primer set and the NS5 primer set has a fluorescent quenching group modified at its 5' end and a fluorescent reporter group modified at its 3' end.

5. A kit for HPgV-1 virus LAMP detection according to claim 4, characterized in that: The fluorescent reporter group is selected from at least one of 6-carboxyfluorescein, hexachloro-6-methylfluorescein, VIC fluorescent dye, tetrachloro-6-carboxyfluorescein, carboxy-X-rhodamine, 6-carboxytetramethylrhodamine, 2,7-dimethyl-4,5-dichloro-6-carboxyfluorescein, sulfonylrhodamine, 6-carboxy-4',5-dichloro-2',7'-dimethoxyfluorescein succinimide ester, cyanine 3, cyanine 5 or cyanine 5.

5.

6. A kit for HPgV-1 virus LAMP detection according to claim 4, characterized in that: The fluorescence quenching group is at least one of BHQ1, BHQ2, and BHQ3.

7. A kit for HPgV-1 virus LAMP detection according to claim 1, characterized in that: The isothermal amplification system comprises 10× isothermal amplification buffer, DNA polymerase, MgCl2, dNTP, and nuclease-free water.

8. A kit for HPgV-1 virus LAMP detection according to claim 7, characterized in that: The DNA polymerase is Bst polymerase.

9. A kit for HPgV-1 virus LAMP detection according to claim 1, characterized in that: The method of use specifically includes the following steps: S1. Collect samples to be tested; S2. Add the collected samples into a sample processing solution to extract viral nucleic acid; S3, adding the extracted viral nucleic acid to a kit for HPgV-1 virus LAMP detection, placing it in a thermostat, and performing LAMP amplification at a constant temperature; S4. After the amplification is completed, the amplification product is detected to determine whether the HPgV-1 virus exists in the sample.

10. A kit for HPgV-1 virus LAMP detection according to claim 9, characterized in that: In step S3, the LAMP amplification reaction temperature is 50-65°C and the reaction time is 10-60 minutes.

Citation Information

Patent Citations

  • Goose Pegivirus loop-mediated isothermal amplification detection primer group and kit

    CN113862396A

  • Kit for LAMP detection of BK virus

    CN114107571A